ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1800

Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1567

Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1853

Association of Gut Dysbiosis with Radiographic and Enthesis Involvement, Disease Activity and Duration in Axial Spondyloarthritis. Data from CASTRO Registry

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1880

Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1922

Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1746

Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1790

Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1729

Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1582

Average Follow-up Time After Telemedicine Visit Is Longer Than Conventional Face-to-Face Visit in Outpatient Rheumatology Practice During COVID-19 Pandemic

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1832

Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1762

Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1653

Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1834

Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1831

Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1763

Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].